Biotech Values

[DewDiligence]

> IDIX – Was this news today enough to get the stock back to the 16-18 range within the next few weeks?<

Highly unlikely, IMO. Today’s PR was simply a little more granularity on what IDIX disclosed back in March.

I think that, with patience, you have an excellent chance to do well from the current price level. $25 in two years ($1.5B fully diluted) is pretty easy to imagine with approval of Telbivudine for HBV in the US and EU, provided nothing untoward happens in the phase-3 program for NM283. But I do not see anything earthshaking happening in only a few weeks.